VADT研究:血糖变异性与心血管风险的关系
基于退伍军人事务部糖尿病试验(VADT),对1791例2型糖尿病患者每3个月监测空腹血糖与HbA1c长达84个月,评估血糖变异性与心血管疾病(CVD)的关联。结果显示空腹血糖的变异指标(CV和ARV)在校正包括平均空腹血糖在内的危险因素后仍与CVD显著相关,该关联在强化治疗组明显而标准治疗组不明显;校正基线危险因素后HbA1c各项指标均与CVD无关联。
要点
- 空腹血糖变异指标(CV、ARV)与CVD显著相关,独立于平均空腹血糖等危险因素。
- 空腹血糖变异与CVD的关联仅在强化降糖组明显,标准治疗组未见。
- 校正多种基线危险因素后,HbA1c各项指标均与CVD无关联。
核心结论
- 在VADT中,空腹血糖变异性在标准空腹血糖指标之外参与CVD并发症的发生,其不良后果在强化降糖治疗者中似乎最大。
- 校正多种基线危险因素后,HbA1c各项指标均与CVD无关联。
研究设计与样本
- VADT研究,对1791例患者每3个月测量空腹血糖和HbA1c,最长随访84个月。
- 变异性指标包括空腹血糖和HbA1c的变异系数(CV)与平均真实变异性(ARV),并分析总体均值及最大值、最近一次测量值。
主要发现
- 空腹血糖的CV和ARV在校正包括平均空腹血糖在内的其他危险因素后仍与CVD显著相关。
- 分强化治疗组与标准治疗组分析时,该关联在强化治疗组明显,标准治疗组未见。
- 进一步校正严重低血糖发作后,空腹血糖变异性与CVD的关系未改变。
- 校正多种基线危险因素后,HbA1c各项指标均与CVD无关联。
临床怎么用
- 对接受强化降糖治疗的患者,除平均血糖外可关注空腹血糖变异指标(CV、ARV)与CVD风险的关联。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is uncertainty about the importance of glycemic variability in cardiovascular complications in patients with type 2 diabetes. Using the Veterans Affairs Diabetes Trial (VADT), we investigated the association between variation in fasting glucose and glycated hemoglobin (HbA1c) over time and the incidence of cardiovascular disease (CVD) and assessed whether this is influenced by intensive or standard glycemic control. RESEARCH DESIGN AND METHODS: During the VADT, fasting glucose and HbA1c were measured every 3 months for up to 84 months in 1,791 individuals. Variability measures included coefficient of variation (CV) and average real variability (ARV) for fasting glucose and HbA1c. Overall mean glucose and HbA1c measures as well as their maximum and the most recent measurement were also examined. RESULTS: Variability measures (CV and ARV) of fasting glucose were significantly associated with CVD even after adjusting for other risk factors, including mean fasting glucose. When considering separately groups receiving intensive and standard glycemic control, this relationship was evident in the intensive treatment group but not in the standard group. Additional adjustment for severe hypoglycemic episodes did not alter the relationship between fasting glucose variability and CVD. Interestingly, no HbA1c measures were associated with CVD after adjusting for multiple baseline risk factors. CONCLUSIONS: Our analysis indicates that in the VADT, variability of fasting glucose plays a role in the development of CVD complications beyond the influence of standard fasting glucose measures. The adverse consequences of fasting glucose variability on CVD appear greatest in those receiving intensive glucose control.
引用
- Zhou JJ, Schwenke DC, Bahn G, et al. Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2018. PMID: 30082325. doi:10.2337/dc18-0548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。